Status:
UNKNOWN
Identification of Novel Inflammation-related Biomarkers for Early Detection of Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
Lead Sponsor:
University Hospital, Essen
Conditions:
Cardiotoxicity
Breast Cancer
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to identify possible set of inflammatory biomarkers before, during and after anthracycline-based chemotherapy in breast cancer patients to identify (sub)clinical chemotherapy-related c...
Eligibility Criteria
Inclusion
- initial diagnosis of breast cancer
- planned Anthracycline-based therapy
- first-line chemotherapy
- first visit before initiation of chemotherapy
Exclusion
- previous chemotherapy
- medical history of cardiac disease
- inflammation-modulating medication
- medication with RAS inhibitors
- pregnancy
- autoimmune disease
- drug addictions
- unwilling or unable to provide informed consent
Key Trial Info
Start Date :
April 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT05298072
Start Date
April 1 2022
End Date
December 1 2023
Last Update
March 28 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.